How often should lasting effects from lurbinectedin be assessed?
The provided information does not specify an assessment interval for “lasting effects” of lurbinectedin. It only refers to “lasting effects” in general terms without stating how frequently they should be measured.
What counts as a “lasting effect” in lurbinectedin monitoring?
No details are given on which outcomes are meant (for example, tumor response durability, survival endpoints, or longer-term side effects), so the required frequency cannot be determined from the available text.
Is there a standard follow-up schedule implied for lurbinectedin?
No schedule is included in the provided information. Without a study protocol, label text, or guideline describing the follow-up cadence, the assessment frequency cannot be answered accurately.
What I need to give you the right interval
If you share the specific source text (for example, a clinical protocol section or the prescribing information passage that mentions “lasting effects”), I can extract the exact timing it requires.
Sources
No sources were provided in the prompt.